Oral beta-lactam step down in bacteremic E. coli urinary tract infections
Stephan Saad, Neil Mina, Colin Lee, Kevin Afra, Stephan Saad, Neil Mina, Colin Lee, Kevin Afra
Abstract
Background: Literature is scarce regarding oral step down to beta-lactams in bacteremic urinary tract infections. Oral fluoroquinolones are an accepted and common step down for bacteremic urinary tract infections; however, their use is associated with mounting safety concerns. We compared clinical cure in patients with E. coli bacteremic urinary tract infections who were stepped down to oral beta-lactams compared to oral fluoroquinolones.
Methods: This multicentre retrospective cohort study included patients with first positive concurrent urine and blood cultures from January 2016 to December 2016. Patients were included if they received empiric intravenous beta-lactam therapy with step down to either oral beta-lactam or fluoroquinolone for treatment completion. The primary outcome was clinical cure. Secondary outcomes were length of hospitalization, all-cause mortality and C. difficile infection. Multivariate analysis and propensity score were used to control for confounding.
Results: A total of 207 patients were identified with bacteremic E.coli urinary tract infections. Clinical cure was achieved in 72/77 (94%) in the oral beta-lactam group versus 127/130 (98%) in the oral fluoroquinolone group (absolute difference - 4.2, 95% confidence interval [CI] -10.3 to 1.9%, p = 0.13). The adjusted odds ratio (OR) for clinical cure with oral beta-lactams was 0.31 (95% CI 0.05-1.90, p = 0.21); propensity score adjusted analysis showed a similar result. There was no statistically significant difference in secondary outcomes.
Conclusions: Oral beta-lactams appear to be a safe and effective step down option in bacteremic E. coli urinary tract infections compared to oral fluoroquinolones.
Keywords: Antibiotics; E. coli; Gram negative bacteremia; Oral step down; Urinary tract infection.
Conflict of interest statement
No competing interests to declare.
References
- Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007;45:273–280. doi: 10.1086/519268.
- Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in outpatient urinary isolates: final results from the north American urinary tract infection collaborative Alliance (NAUTICA) Int J Antimicrob Agents. 2005;26:380–388. doi: 10.1016/j.ijantimicag.2005.08.003.
- Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–e120. doi: 10.1093/cid/ciq257.
- U.S. Food & Drug Administration . FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. 2016.
- U.S. Food & Drug Administration . FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 2016.
- U.S. Food & Drug Administration . FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. 2018.
- U.S. Food & Drug Administration . FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018.
- Health Canada . Summary safety review - Oral FLUOROQUINOLONES - assessing the potential risk of retinal detachment. 2016.
- Health Canada . Summary safety review - Fluoroquinolones - assessing the potential risk of persistent and disabling side effects. 2017.
- European Medicines Agency . Quinolone- and fluoroquinolone-containing medicinal products. 2019.
- Robinson JL, Finlay JC, Lang ME, Bortolussi R. Canadian Paediatric society, infectious diseases and immunization committee, community Paediatrics committee. Urinary tract infections in infants and children: diagnosis and management. Paediatr Child Health. 2014;19:315–325. doi: 10.1093/pch/19.6.315.
- Angel JL, O’Brien WF, Finan MA, Morales WJ, Lake M, Knuppel RA. Acute pyelonephritis in pregnancy: a prospective study of oral versus intravenous antibiotic therapy. Obstet Gynecol. 1990;76:28–32.
- Millar LK, Wing DA, Paul RH, Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol. 1995;86:560–564. doi: 10.1016/S0029-7844(95)80016-6.
- Wing DA, Hendershott CM, Debuque L, Millar LK. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. Obstet Gynecol. 1998;92:249–253.
- Wing DA, Hendershott CM, Debuque L, Millar LK. Outpatient treatment of acute pyelonephritis in pregnancy after 24 weeks. Obstet Gynecol. 1999;94:683–688.
- Sanchez M, Collvinent B, Miró O, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emerg Med J. 2002;19:19–22. doi: 10.1136/emj.19.1.19.
- Monmaturapoj T, Montakantikul P, Mootsikapun P, Tragulpiankit P. A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis. Int J Infect Dis. 2012;16:e843–e849. doi: 10.1016/j.ijid.2012.07.009.
- Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287.
- Tamma PD, Conley AT, Cosgrove SE, et al. Association of 30-day mortality with Oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia. JAMA Intern Med. 2019;179(3):316–323. doi: 10.1001/jamainternmed.2018.6226.
- Mercuro NJ, Stogsdill P, Wungwattana M. Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus β-lactams. Int J Antimicrob Agents. 2018;51:687–692. doi: 10.1016/j.ijantimicag.2017.12.007.
- Punjabi C, Tien V, Meng L, Deresinski S, Holubar M. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ß-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis. Open Forum Infect Dis. 2019;6:ofz364. doi: 10.1093/ofid/ofz364.
- Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68:1951–1961. doi: 10.1093/jac/dkt129.
- Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17:411–421. doi: 10.1016/S1473-3099(16)30514-X.
- Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415–424. doi: 10.1056/NEJMoa1808312.
- Li H-K, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380:425–436. doi: 10.1056/NEJMoa1710926.
Source: PubMed